药剂师对苏格兰先进药剂师处方实施障碍和促进因素的看法:使用规范化过程理论进行定性研究
Mairi-Anne McLean1,2, Paul Forsyth3, Anne C Boyter4
1NHS Greater Glasgow and Clyde, Glasgow, UK. mairi-anne.mclean@nhs.scot.
International journal of clinical pharmacy
|October 6, 2025
概括
药剂师支持先进的处方,但实施面临挑战. 关键的障碍包括缺乏共享的理解,不一致的角色和有限的战略对齐,阻碍了先进药剂师处方的广泛采用.
科学领域:
- 制药实践 制药实践 制药实践
- 医疗保健政策 医疗保健政策
- 医疗保健服务研究 医疗服务研究
背景情况:
- 医疗保健系统需要能够自主提供先进护理的专业人员.
- 了解药剂师对先进处方的看法对于可持续实施至关重要.
- 先进的药剂师处方包括在复杂和高风险情况下的自主实践.
研究的目的:
- 探索药剂师对障碍和促进苏格兰药剂师处方的先进障碍的看法.
- 确定影响先进药剂师处方的嵌入和可持续性的因素.
主要方法:
- 半结构面试与苏格兰全国卫生服务药剂师.
- 有目的的抽样,以确保不同的专业背景和处方活动.
- 使用规范化过程理论 (NPT) 和主题框架分析进行分析.
主要成果:
- 在所有"不扩散核武器条约"的构建中,都发现了障碍和促进因素.
- 推动因素包括对高级处方者角色的个人理解;障碍因素包括缺乏共同理解.
- 缺乏适当的角色,培训,基础设施,信心和多学科评估是重要的障碍.
结论:
- 个人药剂师致力于先进的处方,但系统性问题阻碍了广泛实施.
- 解决缺乏共享的理解,不一致的角色和战略对齐至关重要.
- 结果为嵌入和维持先进的药剂师处方实践提供了见解.
相关概念视频
Factors Affecting Drug Distribution: Physiological Barriers
651
Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
651
Drug Abuse and Addiction: Pharmacological Phenomena
1.1K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.1K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
241
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
241
Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Dosage Regimens: Partial Pharmacokinetic Parameters
132
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
132


